- Pfizer (PFE, Financial) is under investigation for potentially delaying COVID vaccine results, affecting the 2020 U.S. election.
- Analysts' average price target for Pfizer suggests a significant upside from the current price.
- The stock is currently rated as "Hold" by brokerage firms based on consensus recommendations.
The House Judiciary Committee has launched an investigation into Pfizer Inc. (PFE) amid allegations that the pharmaceutical giant intentionally postponed the release of successful COVID-19 vaccine trial results. This delay is alleged to have played a role in the dynamics of the 2020 U.S. presidential election. Sources claim that former Pfizer scientist Phil Dormitzer revealed that testing procedures were decelerated to withhold crucial findings. In response, Pfizer has firmly denied these accusations, maintaining that their actions were in accordance with FDA guidelines.
Analyst Price Predictions
According to data compiled from 21 analysts, the one-year price target for Pfizer Inc. (PFE, Financial) averages at $28.85. The projections display a range with a high point of $41.43 and a low of $23.00. This forecast indicates a potential upside of 28.50% from the current trading price of $22.46. Investors can explore more detailed predictions on the Pfizer Inc. (PFE) Forecast page.
Brokerage Recommendations
The consensus among 25 brokerage firms places Pfizer Inc.'s (PFE, Financial) average recommendation at 2.6, which corresponds to a "Hold" status. This rating utilizes a scale from 1 to 5, with 1 representing a Strong Buy and 5 indicating a Sell. This consensus reflects a cautious approach amidst ongoing investigations and market conditions.
GuruFocus GF Value Insights
GuruFocus provides an estimated GF Value for Pfizer Inc. (PFE, Financial), predicting a value of $27.25 in one year. This estimation suggests a potential upside of 21.35% from the current price of $22.455. The GF Value is derived from an analysis of historical trading multiples, past business growth, and projected future performance. Those interested in a more comprehensive analysis can visit the Pfizer Inc. (PFE) Summary page.
